School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia.
Clin Chem. 2012 Oct;58(10):1476-84. doi: 10.1373/clinchem.2012.190199. Epub 2012 Aug 21.
Resolvins and protectins are families of local lipid mediators generated from the n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) during self-limited resolution of inflammation. We aimed to develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay to measure these lipid mediators in human blood following n-3 fatty acid supplementation and to determine whether the blood collection method affects their measured concentration.
Blood samples from 20 healthy volunteers enrolled in an n-3 fatty acid supplementation trial were collected in EDTA, heparin, or citrate, or prepared as serum after volunteers had undergone 3 weeks of supplementation. Plasma or serum was purified by solid-phase chromatography and analyzed with LC-MS/MS.
The assay identified 18R/S-hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic acid (18R/S-HEPE); 17S-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid (17R/S-HDHA); 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid (RvD1); 7S,8R,17R-trihydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoicacid (17R-RvD1); 7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid (RvD2); 10S,17S-dihydroxy-4Z,7Z,11E,13Z,15E,19Z-docosahexaenoicacid (10S,17S-DiHDHA); and 10R,17S-dihydroxy-4Z,7Z,11E,13E,15Z,19Z-docosahexaenoic acid (protectin D1, PD1). The limits of detection and quantification were 3 pg and 6 pg on-column, respectively. The pathway precursors 18R/S-HEPE and 17R/S-HDHA, but not the resolvins, were lower in serum compared with plasma. After n-3 fatty acid supplementation, mean (SD) EDTA plasma concentrations were: 18R/S-HEPE 386 (56) pg/mL, 17R/S-HDHA 365 (65) pg/mL, RvD2 26 (4) pg/mL, RvD1 31 (5) pg/mL, and 17R-RvD 161 (7) pg/mL. 10S,17S-DiHDHA and PD1 concentrations were below the limit of quantification.
This is the first study reporting 17R/S-HDHA, RvD1, and RvD2 concentrations measured in human blood following oral n-3 fatty acid supplementation. The concentrations of the antiinflammatory lipid mediators RvD1 and RvD2 were within the biological range known to have antiinflammatory and proresolving activities in isolated human leukocytes and in in vivo studies in mice.
解析素和保护素是内源性脂质介质家族,由 n-3 脂肪酸二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)在炎症自限性消退过程中产生。我们旨在开发一种液相色谱-串联质谱(LC-MS/MS)测定法,用于测量 n-3 脂肪酸补充后人体血液中的这些脂质介质,并确定血液采集方法是否会影响其测量浓度。
20 名参加 n-3 脂肪酸补充试验的健康志愿者的血液样本分别用 EDTA、肝素或柠檬酸盐采集,或在志愿者接受 3 周补充后制备为血清。用固相色谱法纯化血浆或血清,并进行 LC-MS/MS 分析。
该测定法鉴定出 18R/S-羟基-5Z,8Z,11Z,14Z,16E-二十碳五烯酸(18R/S-HEPE);17S-羟基-4Z,7Z,10Z,13Z,15E,19Z-二十二碳六烯酸(17R/S-HDHA);7S,8R,17S-三羟基-4Z,9E,11E,13Z,15E,19Z-二十二碳六烯酸(RvD1);7S,8R,17R-三羟基-4Z,9E,11E,13Z,15E,19Z-二十二碳六烯酸(17R-RvD1);7S,16R,17S-三羟基-4Z,8E,10Z,12E,14E,19Z-二十二碳六烯酸(RvD2);10S,17S-二羟基-4Z,7Z,11E,13Z,15E,19Z-二十二碳六烯酸(10S,17S-DiHDHA);和 10R,17S-二羟基-4Z,7Z,11E,13E,15Z,19Z-二十二碳六烯酸(保护素 D1,PD1)。检测限和定量限分别为 3pg 和 6pg 柱上。与血浆相比,血清中的途径前体 18R/S-HEPE 和 17R/S-HDHA 较低,但解析素则不然。在 n-3 脂肪酸补充后,EDTA 血浆浓度的平均值(SD)为:18R/S-HEPE 386(56)pg/ml,17R/S-HDHA 365(65)pg/ml,RvD2 26(4)pg/ml,RvD1 31(5)pg/ml 和 17R-RvD 161(7)pg/ml。10S,17S-DiHDHA 和 PD1 浓度低于定量限。
这是第一项报道口服 n-3 脂肪酸补充后人体血液中 17R/S-HDHA、RvD1 和 RvD2 浓度的研究。抗炎脂质介质 RvD1 和 RvD2 的浓度处于已知在分离的人类白细胞和在小鼠体内研究中具有抗炎和促解决活性的生物学范围内。